Regidor B - Search Results

1

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.

Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Preugschat K, Feinstein AJ, Spektor TM, Berenson JR. Stampfer SD, et al. Among authors: regidor b. Leukemia. 2021 Dec;35(12):3534-3541. doi: 10.1038/s41375-021-01354-7. Epub 2021 Jul 29. Leukemia. 2021. PMID: 34326466 Free PMC article.

2

Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.

Regidor B, Swift R, Eades B, Emamy-Sadr M, Tarhini F, Spektor TM, Berenson JR. Regidor B, et al. Ann Hematol. 2021 Apr;100(4):1079-1085. doi: 10.1007/s00277-020-04351-5. Epub 2020 Nov 25. Ann Hematol. 2021. PMID: 33237342

3

Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Regidor B, Goldwater MS, Wang J, Bujarski S, Swift R, Eades B, Emamy-Sadr M, Eshagian S, Schwartz G, Spektor TM, Berenson JR. Regidor B, et al. Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14. Ann Hematol. 2021. PMID: 33987683

4

Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.

Bujarski S, Goldwater MS, Regidor BS, Jew S, Daniely D, Swift RA, Eades BM, Emamy-Sadr M, Souther E, Li M, Wang C, Xu N, Chen H, Spektor TM, Berenson JR. Bujarski S, et al. Among authors: regidor bs. Eur J Haematol. 2021 Sep;107(3):318-323. doi: 10.1111/ejh.13666. Epub 2021 Jun 14. Eur J Haematol. 2021. PMID: 33993536

5

Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.

Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Regidor B, Sutanto C, Berenson JR. Bujarski S, et al. Among authors: regidor b. Target Oncol. 2021 Jul;16(4):503-515. doi: 10.1007/s11523-021-00821-6. Epub 2021 Jun 7. Target Oncol. 2021. PMID: 34097243

6

Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination.

Stampfer SD, Goldwater MS, Bujarski S, Regidor B, Zhang W, Feinstein AJ, Swift R, Eshaghian S, Vail E, Berenson JR. Stampfer SD, et al. Among authors: regidor b. Clin Infect Pract. 2022 Jan;13:100130. doi: 10.1016/j.clinpr.2021.100130. Epub 2021 Dec 9. Clin Infect Pract. 2022. PMID: 34909634 Free PMC article.

7

Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.

Regidor BS, Siddiqi D, Beatty BM, Goldwater MS, Jew S, Bujarski S, Swift R, Kim S, Berenson JR. Regidor BS, et al. Eur J Haematol. 2023 Feb;110(2):222-223. doi: 10.1111/ejh.13896. Epub 2022 Nov 20. Eur J Haematol. 2023. PMID: 36367357 No abstract available.

8

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.

Berenson JR, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Swift R, Eades BM, Bujarski S, Regidor B, Kim C, Kim S, Vescio R. Berenson JR, et al. Among authors: regidor b. Br J Haematol. 2023 Mar;200(6):722-730. doi: 10.1111/bjh.18593. Epub 2022 Dec 9. Br J Haematol. 2023. PMID: 36482815

9

Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.

Stampfer SD, Bujarski S, Goldwater MS, Jew S, Regidor B, Chen H, Xu N, Li M, Fung E, Swift R, Beatty B, Eshaghian S, Berenson JR. Stampfer SD, et al. Among authors: regidor b. Cancer Rep (Hoboken). 2023 May;6(5):e1803. doi: 10.1002/cnr2.1803. Epub 2023 Mar 9. Cancer Rep (Hoboken). 2023. PMID: 36891732 Free PMC article.

10

Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study.

Regidor BS, Jew S, Goldwater MS, Beatty BM, Bujarski S, ElSayed A, Danis R, Kim S, Swift R, Schwartz G, Berenson JR. Regidor BS, et al. Eur J Haematol. 2023 Oct;111(4):628-635. doi: 10.1111/ejh.14057. Epub 2023 Jul 24. Eur J Haematol. 2023. PMID: 37485542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page